283
Views
14
CrossRef citations to date
0
Altmetric
Reviews

Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

, MD PhD, , MD PhD, , MD PhD, , MD, , MD PhD, , MD PhD, , MD PhD, , MD PhD, , MD PhD, , MD PhD, , MD PhD & , MD PhD show all
Pages 159-174 | Published online: 23 Dec 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

E Vrdoljak, L Torday, C Szczylik, G Kharkevich, S Bavbek & A Sella. (2016) Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe. Expert Opinion on Pharmacotherapy 17:1, pages 93-104.
Read now
Anna M Czarnecka, Cezary Szczylik & Brian Rini. (2014) The use of sunitinib in renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy 14:9, pages 983-999.
Read now

Articles from other publishers (12)

Saadullah Khattak, Mohd Ahmar Rauf, Nazeer Hussain Khan, Qian-Qian Zhang, Hao-Jie Chen, Pir Muhammad, Mohammad Azam Ansari, Mohammad N. Alomary, Muhammad Jahangir, Chun-Yang Zhang, Xin-Ying Ji & Dong-Dong Wu. (2022) Hydrogen Sulfide Biology and Its Role in Cancer. Molecules 27:11, pages 3389.
Crossref
Liang Luo, Haiyi Zhou & Hao Su. (2021) Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis. BMC Cancer 21:1.
Crossref
Zeyu Liu, Yuxiang Wan, Ming Yang, Xuewei Qi, Zhenzhen Dong, Jinchang Huang & Jingnan Xu. (2020) Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas. Cancer Cell International 20:1.
Crossref
Xingliang Feng, Meng Zhang, Jialin Meng, Yongqiang Wang, Yi Liu, Chaozhao Liang & Song Fan. (2020) Correlating Transcriptional Networks to Papillary Renal Cell Carcinoma Survival: A Large-Scale Coexpression Analysis and Clinical Validation. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 28:3, pages 285-297.
Crossref
Dinesh Kumar Chellappan, Jestin Chellian, Zhao Yin Ng, Yan Jinn Sim, Chiu Wei Theng, Joyce Ling, Mei Wong, Jia Hui Foo, Goh Jun Yang, Li Yu Hang, Saranyah Nathan, Yogendra Singh & Gaurav Gupta. (2017) The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomedicine & Pharmacotherapy 96, pages 768-781.
Crossref
L. Bošković, M. Gašparić, B. Petrić Miše, M. Petković, D. Gugić, M. Ban, M. Jazvić, N. Dabelić, I. Belac Lovasić & E. Vrdoljak. (2017) Optimisation of breast cancer patients' follow-up - potential way to improve cancer care in transitional countries. European Journal of Cancer Care 26:4, pages e12514.
Crossref
Adam F. Tracz, Cezary Szczylik, Camillo Porta & Anna M. Czarnecka. (2016) Insulin-like growth factor-1 signaling in renal cell carcinoma. BMC Cancer 16:1.
Crossref
Anna M Czarnecka, Anna Kornakiewicz, Fei Lian & Cezary Szczylik. (2015) Future perspectives for mTOR inhibitors in renal cell cancer treatment. Future Oncology 11:5, pages 801-817.
Crossref
Anna M Czarnecka, Wojciech Kukwa, Anna Kornakiewicz, Fei Lian & Cezary Szczylik. (2014) Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. Future Oncology 10:15, pages 2493-2508.
Crossref
Zheng-Xu Wang, Jun-Li Li, Jun-Xia Cao, Yi-Shan Liu, Duo Li, Xiao-Yan Zhang, Min Wang, Min Wu, Bei-Lei Xu, Jin-Long Liu & Hai-Bo Wang. (2014) Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis. Immunotherapy 6:6, pages 787-795.
Crossref
Anna M Czarnecka, Anna Kornakiewicz, Wojciech Kukwa & Cezary Szczylik. (2014) Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. Future Oncology 10:6, pages 1095-1111.
Crossref
Alexandr Poprach, Tomas Pavlik, Bohuslav Melichar, Katerina Kubackova, Zbynek Bortlicek, Marek Svoboda, Radek Lakomy, Rostislav Vyzula, Igor Kiss, Ladislav Dusek & Tomas Buchler. (2014) Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology: Seminars and Original Investigations 32:4, pages 488-495.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.